ImmunGene, Inc. is a privately held drug discovery and development company, developing next generation of monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases. We are leveraging promising science to tap the power of the immune systems to develop therapeutic antibodies that are highly optimized for efficacy and a superior safety profile. Our technology allows us to fuse cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines. We are working to make our novel drug candidates for treating diseases that affect tens of millions of people worldwide. Our primary focus is on safe and effective treatments for cancer. We also has programs underway to treat other potentially devastating diseases, including infections.
Looking for a particular ImmunGene, Inc. employee's phone or email?
The ImmunGene, Inc. annual revenue was $9 million in 2026.
1 people are employed at ImmunGene, Inc..
ImmunGene, Inc. is based in Thousand Oaks, California.
The NAICS codes for ImmunGene, Inc. are [54, 541714, 5417, 54171, 541].
The SIC codes for ImmunGene, Inc. are [873, 87].